Frankfurt - Delayed Quote EUR

BeiGene, Ltd. (49BA.F)

208.00
+4.00
+(1.96%)
At close: May 9 at 3:53:11 PM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
4,175,868
3,810,241
2,458,779
1,415,921
1,176,283
Cost of Revenue
634,156
594,089
379,920
286,475
164,906
Gross Profit
3,541,712
3,216,152
2,078,859
1,129,446
1,011,377
Operating Expense
3,837,461
3,784,351
3,286,595
2,919,111
2,450,112
Operating Income
-295,749
-568,199
-1,207,736
-1,789,665
-1,438,735
Net Non Operating Interest Income Expense
37,524
47,836
74,009
52,480
-15,757
Other Income Expense
-10,450
-12,638
307,891
-223,852
15,904
Pretax Income
-268,675
-533,001
-825,836
-1,961,037
-1,438,588
Tax Provision
123,691
111,785
55,872
42,778
19,228
Net Income Common Stockholders
-392,366
-644,786
-881,708
-2,003,815
-1,457,816
Diluted NI Available to Com Stockholders
-392,366
-644,786
-881,708
-2,003,815
-1,457,816
Basic EPS
-3.64
-6.11
-8.45
-19.37
-15.21
Diluted EPS
-3.64
-6.11
-8.45
-19.37
-15.21
Basic Average Shares
105,951.78
105,288.22
104,387.27
103,133.04
92,785.39
Diluted Average Shares
107,013.32
105,288.22
104,387.27
103,133.04
92,785.39
Total Operating Income as Reported
-295,749
-568,199
-1,207,736
-1,789,665
-1,438,735
Total Expenses
4,471,617
4,378,440
3,666,515
3,205,586
2,615,018
Net Income from Continuing & Discontinued Operation
-392,366
-644,786
-881,708
-2,003,815
-1,457,816
Normalized Income
-392,366
-644,786
-881,708
-2,003,815
-1,457,816
Interest Income
37,524
47,836
74,009
52,480
--
Net Interest Income
37,524
47,836
74,009
52,480
-15,757
EBIT
-295,749
-568,199
-1,207,736
-1,789,665
-1,438,735
EBITDA
-116,476
-396,437
-1,120,061
-1,723,387
-1,392,278
Reconciled Cost of Revenue
634,156
594,089
379,920
286,475
119,199
Reconciled Depreciation
179,273
171,762
87,675
66,278
46,457
Net Income from Continuing Operation Net Minority Interest
-392,366
-644,786
-881,708
-2,003,815
-1,457,816
Normalized EBITDA
-116,476
-396,437
-1,120,061
-1,723,387
-1,392,278
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 2/10/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BPTH Bio-Path Holdings, Inc.
0.1630
-0.06%
 
SCPH scPharmaceuticals Inc.
2.4400
-2.79%
 
NAMS NewAmsterdam Pharma Company N.V.
18.37
-4.67%
 
BPMC Blueprint Medicines Corporation
97.17
-1.61%
 
LEGN Legend Biotech Corporation
31.78
-0.81%
 
OMER Omeros Corporation
6.18
-2.06%
 
KPTI Karyopharm Therapeutics Inc.
6.01
-2.28%
 
CRIS Curis, Inc.
1.8900
-10.00%
 
TVTX Travere Therapeutics, Inc.
20.02
-2.05%
 
NUVB Nuvation Bio Inc.
2.0900
-0.48%